



IGL/SE/2025-26/05

16th May, 2025

The Manager (Listing)

The Manager (Listing)

BSE Limited National Stock Exchange of India Limited

1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G,

Rotunda Building, P.J. Towers, Bandra Kurla Complex,

Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai- 400 051

Scrip Code: 500201 Symbol: INDIAGLYCO

Dear Sirs,

<u>Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"):</u>

- 1. <u>Withdrawal of Composite Scheme of Arrangement involving amalgamation and demerger ("Original Scheme"); and</u>
- 2. Approval of Scheme of Arrangement involving demerger ("Modified Scheme").
- (A) Further to our communication dated 4th February 2025 wherein we had informed of the decision of the Board of Directors approving the Original Scheme involving:

Part I: Amalgamation of Kashipur Holding Limited ("**KHL**") into the India Glycols Limited ("Company" or "IGL" or "Transferee Company" or "Demerged Company");

Part II: Demerger of:

- a. Bio Pharma Undertaking into a separate Company namely "Ennature Bio Pharma Limited" ("Resultant Company-1"); and
- b. Spirits and Biofuel Undertaking into a separate Company namely "IGL Spirits Limited" ("Resultant Company-2").
- **(B)** Post deliberations, in order to continue on value creation for its stakeholders, the Board of Directors in its meeting held today i.e. 16th May 2025 has decided to exclusively focus on Part II of the Original Scheme, i.e. Modified Scheme:
 - The demerger of the Bio Pharma Undertaking into Ennature Bio Pharma Limited; and
 - The demerger of the Spirits and Biofuel Undertaking into IGL Spirits Limited.
- (C) The Modified Scheme represents Part II of the Original Scheme in its entirety and no modification or change in any manner whatsoever is proposed in Part II. Accordingly, Part I which deals with the amalgamation of KHL into IGL will no longer form part of the Modified Scheme and has been deleted from the Modified Scheme.

Phone: +91 5947 269000 / 269500 Fax: +91 5947 275315, 269535 CIN: L24111UR1983PLC009097





- **(D)** As a result, the Original Scheme would be withdrawn. Such withdrawal and simultaneous approval of Modified Scheme would, therefore, not have any impact on the interest of the stakeholders including public shareholders as they will continue to own the same percentage of shares in IGL and Resulting Companies.
- **(E)** The Company would make appropriate statutory filings in this regard, in due course.

Accordingly, the information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 is enclosed in the prescribed format in **Annexure 1**.

We request you to take the above information on record.

The above said board meeting commenced at 15.45 Hrs. and concluded at 17.30 Hrs.

Thanking you,

Yours truly,

For India Glycols Limited

Ankur Jain Head (Legal) & Company Secretary Encl: A/a

Phone: +91 5947 269000 / 269500 Fax: +91 5947 275315, 269535

CIN: L24111UR1983PLC009097





ANNEXURE 1

Disclosure of information pursuant to Regulation 30 of SEBI Listing Regulations, read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024.

Details of the proposed scheme:

S	Particulars	Details
No.		
1.	Name of the entity(ies) forming part of the proposed scheme and their area of business	India Glycols Limited ("Demerged Company" or "IGL"), is a public listed Company incorporated under the provisions of the Companies Act, 1956 under the corporate identity number L24111UR1983PLC009097 and having its registered office at A-1, Industrial Area, Bazpur Road, Kashipur, Udham Singh Nagar, Uttarakhand, India – 244713. IGL is in business of manufacturing and marketing of Bio-based Specialities & Performance Chemicals such as Bio-Polymers, Green Solvents, Specialty Derivatives, Industrial Gases, Potable spirits, ENA (Extra Neutral Alcohol), Ennature Biopharma and Bio Fuels. The equity shares of IGL are listed on the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE").
		Ennature Bio Pharma Limited (formerly known as Ennature Bio Pharma Private Limited) (the "Resulting Company 1/EBL"), is a public Company incorporated under the provisions of the Companies Act, 2013 under the corporate identity number U24290UR2021PLC013005. It is engaged in the business of producing nutraceuticals, phytochemicals, and natural plant-based active pharmaceutical ingredients. The Resulting Company 1 is a wholly-owned Company of the Demerged Company.
		IGL Spirits Limited (the "Resulting Company 2/ISL"), is a public Company incorporated under the provisions of the Companies Act, 2013 under the corporate identity number U11011UT2024PLC018229. It is engaged in the business of manufacturing and production of alcoholic & non-alcoholic beverages and ethanol & alcohol and related products. The Resulting Company 2 is a whollyowned Company of the Demerged Company.

Corporate Office: 3A, Shakespeare Sarani, Kolkata - 700071, Phone: +91 33 22823585, 22823586

Works & Registered Office: A-1, Industrial Area, Bazpur Road, Kashipur - 244713, Distt. Udham Singh Nagar (Uttarakhand)

Phone: +91 5947 269000 / 269500 Fax: +91 5947 275315, 269535

CIN: L24111UR1983PLC009097





						In la	khs
		Companies	Net worth 31st Dec 20		Total rev 31st Dec	enue as or	
		India Glycols Limited	1,82,166.28		6,84,982.00		
		Ennature Bio Pharma Limited	(0.33)		Nil		
		IGL Spirits Limited (Incorporated on 25 th November 2024)	1			Nil	
2.	Brief details of the	Biopharma Unde	rtaking –	Producti	ion of no	utraceutic	als,
	division(s) to be	phytochemicals,	_				
	demerged	pharmaceutical			-		
			-				
		Spirits and Biofo					
		production of a				_	ges,
		ethanol & alcoh	ol and othe	er relate	d produc	cts.	
3.	Turnover of the						
ا ا	demerged division	Particulars		Turno	ver as	%	1
	and as	Tarriculais		Turnover as per FY 23-24		/0	
	percentage to the			financials in			
	total turnover of			INR Crs			
	the listed entity in	Biopharma		250.47		3.16%	
	the immediately	Undertaking					
	preceding	Spirits and	Biofuel	6,188.82		78.15%	
	financial year /	Undertaking					
	based on financials of the	Remaining b	usiness		79.48	18.69%	
	last financial year	Total		7,91	8.77	100%	
4.	Rationale for the	The Demerged	Company	is a lea	ding are	en chemi	cal
	proposed scheme	Company. It has					
		and currently houses four segments, namely, bio-based					
		specialties and performance chemicals, potable spirits,					
		ennature biopharma and bio-fuel. Given its diversified					
		business, it has become imperative for the Demerged Company to reorient and reorganize itself in a manner					
		that allows imp		_			
		businesses. With	~ ~			Demerg	
		Company is d	•		-	_	
		efficiency. It will			-	•	
		and performance chemicals business. While each of the					
		above businesses may be subject to industry specific risks,					
		business cycles	and opera	ate inter	r alia ur	der differ	ent

CIN: L24111UR1983PLC009097





market dynamics, they have a significant potential for growth and profitability.

The Scheme proposes to reorganise and segregate the shareholdings of Demerged Company in various businesses and thus proposes the demerger of Spirits and Biofuel Undertaking and Biopharma Undertaking from Demerged Company to the Resulting Companies. The demerger of the Demerged Undertakings from the Demerged Company to the Resulting Companies will result in the equity shares of the Resulting Companies becoming listed on the National Stock Exchange Limited and BSE Limited, with the Resulting Companies focussing exclusively on their respective undertakings and capable of independent valuation and participation therein by any suitable investor interested in such businesses, in the future.

The proposed restructuring pursuant to this Scheme is expected, inter alia, to result in following benefits:

- (i) Segregation and unbundling of the Spirits and Biofuel Undertaking and Biopharma Undertaking of the Demerged Company into the Resulting Companies will offer the following benefits:
 - a. Each business will have a clear focus, leading to improved management and resource allocation for growth.
 - b. The demerger will enable independent growth for each business, attracting the right talent, offering better opportunities for employees.
 - c. The demerger may create a potential to unlock value for stakeholders by drawing focused investors.
 - d. Each business will manage its capital, investments, and resources based on its specific needs, ensuring more efficient capital use.
 - e. Each business will adhere to regulations that are specific to its industry.
 - f. Separating the businesses will reduce the risk of one business affecting the others.





			(ii) The proposed restructuring is in the interest of the shareholders, creditors, employees, and other					
			stakeholders in each of the companies.					
5.	Brief details	of						
	change	in						
	shareholding pattern (if any)	o.f	face value INR 10 (Indian Rup					
	all entities	Oi	shareholders of IGL holding 3 (Three) shares (Indian Rupees Ten) each.				G2 OI HAK TO	
			Upon the scheme being effective on the Effective Date, for demerger, ISL shall issue 1 (One) Equity Share having face value INR 10 (Indian Rupees Ten) each, to the shareholders of IGL holding 1 (One) shares of INR 10 (Indian Rupees Ten) each.					
			Pre and post-shareholding pattern of IGL					
			Particulars	March 20				
				No. Equity	of Shareholdir	ng No. o of Equity	f Shareholding as % of voting	
				Shares	voting right		rights	
			Promoters	1,88,91,03	32 61.01	1,88,91,032	2 61.01	
			Public	1,20,70,4	38.99	1,20,70,468	3 38.99	
			Total	3,09,61,50	00 100	3,09,61,500	100	
				ost-share	holding patte		on demerger	
			Pre and po	Pre-Sche March 2 No. of	holding patte eme (as on 31st 025) Shareholding	Post-Scheme No. of Equity	on demerger * Shareholding	
			Pre and po	Pre-Sche March 2 No. of Equity	holding patte eme (as on 31st 025) Shareholding as % of voting	ern of EBL up	on demerger * Shareholding as % of	
			Pre and po	Pre-Sche March 2 No. of	holding patte eme (as on 31st 025) Shareholding	Post-Scheme No. of Equity	on demerger * Shareholding	
			Pre and po	Pre-Sche March 2 No. of Equity Shares	holding patte eme (as on 31st 025) Shareholding as % of voting rights	Post-Scheme No. of Equity Shares	on demerger * Shareholding as % of voting rights	
			Pre and po	Pre-Sche March 2 No. of Equity Shares 10,000	holding patter the (as on 31st 025) Shareholding as % of voting rights	Post-Scheme No. of Equity Shares 62,97,011 40,23,489	shareholding as % of voting rights	
			Pre and po Particulars Promoters Public Total	Pre-Sche March 2 No. of Equity Shares 10,000	holding patterne (as on 31st 025) Shareholding as % of voting rights 100	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500	shareholding as % of voting rights 61.01 38.99	
			Pre and po Particulars Promoters Public Total *Subject to the	Pre-Sche March 2 No. of Equity Shares 10,000 Nil	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entitions	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 Jement in terms of	shareholding as % of voting rights 61.01 38.99 100 of the Scheme	
			Pre and po Particulars Promoters Public Total *Subject to the	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 porovisions pre-Sche Pre-Sche	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entition (as on 31st eme	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 Jement in terms of	shareholding as % of voting rights 61.01 38.99 100 of the Scheme on demerger	
			Pre and po Particulars Promoters Public Total *Subject to the	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 e provisions pre-Sche March 2	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entity eme (as on 31st 025)	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 ement in terms of the control o	shareholding as % of voting rights 61.01 38.99 100 of the Scheme on demerger	
			Pre and po Particulars Promoters Public Total *Subject to the	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 porovisions pre-Sche Pre-Sche	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entity holding patter eme (as on 31st 025)	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 ement in terms of Post-Scheme No. of	shareholding as % of voting rights 61.01 38.99 100 of the Scheme on demerger	
			Pre and portion of the state of	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 provisions pst-share Pre-Sche March 2 No. of Equity Shares	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entition (as on 31st 025) Shareholding as % of voting as % of voting rights	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 ement in terms of the company of the compa	shareholding as % of voting rights Shareholding as % of voting rights Shareholding as % of voting rights	
			Pre and po Particulars Promoters Public Total *Subject to the	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 provisions pst-share Pre-Sche March 2 No. of Equity	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entition (as on 31st 025) Shareholding as % of voting	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 Tement in terms of the control	shareholding as % of voting rights 61.01 38.99 100 of the Scheme shareholding as % of voting as % of voting as % of voting	
			Pre and portion of the state of	Pre-Sche March 2 No. of Equity Shares 10,000 Nil 10,000 provisions pst-share Pre-Sche March 2 No. of Equity Shares	holding patter eme (as on 31st 025) Shareholding as % of voting rights 100 Nil 100 for fractional entition (as on 31st 025) Shareholding as % of voting as % of voting rights	Post-Scheme No. of Equity Shares 62,97,011 40,23,489 1,03,20,500 ement in terms of the company of the compa	shareholding as % of voting rights Shareholding as % of voting rights Shareholding as % of voting rights	

Corporate Office: 3A, Shakespeare Sarani, Kolkata - 700071, Phone: +91 33 22823585, 22823586

Works & Registered Office: A-1, Industrial Area, Bazpur Road, Kashipur - 244713, Distt. Udham Singh Nagar (Uttarakhand)

Phone: +91 5947 269000 / 269500 Fax: +91 5947 275315, 269535 CIN: L24111UR1983PLC009097





6.	In case of cash	In case of demerger for EBL
	consideration – amount or otherwise share exchange ratio	In consideration of demerger of Bio Pharma Undertaking of IGL into EBL, the following Share Exchange Ratio has been approved: "EBL shall issue 1 (One) Equity Share having face value INR 10 (Indian Rupees Ten) each, to the shareholders of IGL holding 3 (Three) Equity Shares of INR 10 (Indian Rupees Ten) each"
		In case of demerger for ISL In consideration of demerger of Spirits and Biofuel Undertaking of IGL into ISL, the following Share Exchange Ratio has been approved:
		"ISL shall issue 1 (One) Equity Share having face value INR 10 (Indian Rupees Ten) each, to the shareholders of IGL holding 1 (One) Equity Share of INR 10 (Indian Rupees Ten) each".
7.	Whether listing would be sought for the resulting entities	Yes. The shares issued by EBL and ISL shall be listed on BSE Limited and the National Stock Exchange of India Limited subject to necessary approvals.
8.	Details and reasons for other restructuring	The Scheme inter-alia provides for cancellation of the paid-up share capital of EBL and ISL held by IGL. Accordingly, on the Scheme becoming effective, the share capital of EBL and ISL shall stand reduced to the extent of face value of shares held by IGL in EBL and ISL.
9.	Quantitative and/ or qualitative effect of other restructuring	The above cancellation of equity shares of EBL and ISL would be undertaken as an integral part of the Scheme. Such reduction of share capital of EBL and ISL as provided in the Scheme shall be effected as an integral part of the Scheme and the orders of the NCLT sanctioning the Scheme shall be deemed to be an order under Section 66 of the Companies Act, 2013 confirming the reduction
		and no separate sanction under Section 66 of the Companies Act, 2013 will be necessary. EBL and ISL shall not be required to add the words "and reduced" as a suffix to its name consequent upon such reduction.
10.	Details of benefit, if any, to the promoter/promot er group/group companies from such proposed restructuring;	NIL.

Phone: +91 5947 269000 / 269500 Fax: +91 5947 275315, 269535 CIN: L24111UR1983PLC009097